首页> Journal for immunotherapy of cancer> Response to: Correspondence on "Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab" by Gao <i>et al</i>.

Response to: Correspondence on "Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab" by Gao <i>et al</i>.

导出 LinkOut

翻译打印收藏纠错

第一作者： Christopher,Graser

第一单位： Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.;Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA.;Department of Stem Cell and Regenerative Biology, Harvard University, Boston, Massachusetts, USA.

作者： Christopher,Graser ^[1] ; Thomas O,McDonald ^[2] ; Paul J,Catalano ^[3] ; Guru,Sonpavde ^[4] ; Franziska,Michor ^[5]

作者单位： Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.;Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA.;Department of Stem Cell and Regenerative Biology, Harvard University, Boston, Massachusetts, USA. ^[1] Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.;Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA.;Department of Stem Cell and Regenerative Biology, Harvard University, Boston, Massachusetts, USA.;Center for Cancer Evolution, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. ^[2] Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.;Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA. ^[3] M, University of Central Florida, Orlando, Florida, USA.;AdventHealth Cancer Institute, Orlando, Florida, USA. ^[4] Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA michor@jimmy.harvard.edu.;Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA.;Department of Stem Cell and Regenerative Biology, Harvard University, Boston, Massachusetts, USA.;Center for Cancer Evolution, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.;The Eli and Edythe L Broad Institute, Cambridge, Massachusetts, USA.;Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts, USA. ^[5]

关键词 Immunotherapy

DOI 10.1136/jitc-2025-012742

PMID 40537242

发布时间 2025-06-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal for immunotherapy of cancer

2025年13卷6期

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Journal for immunotherapy of cancer

2025年13卷6期

检索历史清除

Response to: Correspondence on "Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab" by Gao <i>et al</i>.

Journal for immunotherapy of cancer

相似文献

同项目论文

Journal for immunotherapy of cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Response to: Correspondence on "Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab" by Gao <i>et al</i>.

Journal for immunotherapy of cancer

相似文献

同项目论文

Journal for immunotherapy of cancer

相关期刊

检索历史清除